Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-Based Chemotherapy in Patients with Chemotherapy Naive Stage IV Non-Small Cell Lung Cancer
This is a multicenter randomized phase II to determine if the administration of standard
platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell
Lung Cancer (NSCLC) will improve the overall response rate (ORR) compared to MK-3475
administered before chemotherapy. Patients will be given Pembrolizumab as maintenance up to 1
year: Carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by
pembrolizumab every 3 weeks for up to 1 year. Pembrolizumab every 3 weeks x 4 cycles followed
by carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by
pembrolizumab every 3 weeks for up to 1 year.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.